Irish medtech company Neuromod is opening its first US subsidiary.

The firm, which specialised in making neuromodulation devices for the treatment of chronic conditions including tinnitus, is to open an office in Illinois.

It is part of the company's plans to enter the US market with its tinnitus treatment, once it gets approval from the Food and Drug Administration.

In order to progress the development, three new executives have been appointed to lead the US team.

Stephanie Glowacki is joining the company as Chief Financial Officer, Dr Tish Ramirez will become Chief Commercial Officer and Holly Dean joins as Director of Commercial Sales.

Between 10% and 15% of the population of the world are thought to suffer from tinnitus or ringing in the ears.

Around 50 million in the US have it, 20 million of whom suffer from the condition chronically.

Neuromod was founded in 2010.

Its Lenire device delivers mild electrical pulses to the tongue combined with sound played through headphones to drive long-term changes or neuroplasticity in the brain to treat tinnitus.

In October of last year Neuromod raised €10.5 million in a Series B financing round to fund its expansion.